Cortex Pharma regains all Ampakine assets, rights from Biovail
As per the new agreement, Cortex will make an upfront payment to Biovail of $200,000, and potential future payments of up to $15.15m based on the achievement of
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.
The study result suggested that INC42 has reduced spleen size in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), when compared with